Evidence map›Paper›PMID 40721672›Full record

ArticleSurgical endoscopy2025

Feasibility and safety assessment of the AGIBOT

Pokhrel Gaurab, Jin Tao, Yunlong Liu, Jinshan Cui, Yafeng Fan, Biao Dong, Shuanbao Yu, Yonghao Zhan, Linfeng Xu, Guangxiang Liu and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pokhrel Gaurab *Department of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Jin Tao *Department of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Yunlong LiuDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Jinshan CuiDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Yafeng FanDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Biao DongDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Shuanbao YuDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Yonghao ZhanDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China.
Linfeng XuDepartment of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjng University, Nanjing, 210008, China.
Guangxiang LiuDepartment of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjng University, Nanjing, 210008, China.
Xuepei ZhangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, China. zhangxuepei@263.net.
Shun ZhangDepartment of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China. explorershun@126.com.
Hongqian GuoDepartment of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China. dr.ghq@nju.edu.cn.

Funding

Henan Provincial Science and Technology Research Project 242102311074Natural Science Foundation of Henan Province 232300420254
6 · The paper itself

Abstract

backgroundRobotic-assisted surgery has become a standard approach for urological procedures, providing enhanced precision, dexterity, and minimally invasive benefits. However, high costs and limited accessibility limits its broader adoption. This study evaluates feasibility and safety of novel AGIBOT

methodsThis prospective, multicenter study evaluated 59 patients undergoing AGIBOT

resultsAll procedures were completed successfully without conversions or major intraoperative complications. For partial nephrectomy, the median operative time was 64 min, blood loss was 50 mL, and median warm ischemia time was 16.5 min, with negative surgical margins in all but one case. For radical prostatectomy, the median operative time was 114.5 min, blood loss was 100 mL, and positive surgical margins were observed in four cases (18%). Renal function remained stable after partial nephrectomy, immediate continence was achieved in 30% of RP patients, improving to full continence at six months in all patients. Two postoperative complications occurred but were not considered related to the robotic system. No major device-related malfunctions were observed and none of the patient's required readmission within 30 days.

conclusionsThe AGIBOT

Indexed as

NephrectomyProstatectomyRobotic Surgical ProceduresAgedBlood Loss, SurgicalFeasibility StudiesFemaleHumansIntraoperative ComplicationsLength of StayMaleMargins of ExcisionMiddle AgedOperative TimeProspective StudiesAGIBOT®Novel systemPartial nephrectomyRadical prostatectomyRobotic surgeryUrology

Identifiers

PMID40721672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.